Data / Form D filings / Verra Therapeutics, Inc.
Verra Therapeutics, Inc.: Form D filing
Verra Therapeutics, Inc., a biotechnology company in Lansing, NY, filed a Form D with the SEC in 2026. The latest, on February 18, 2026, reports $205,000 sold of a $450,000 offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1939 EAST SHORE DR. SUITE 5, Lansing, NY, 14882
- Phone
- (607) 227-6828
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2024
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2111997
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | New notice | $450,000 | $205,000 | $245,000 | 6 | Dec 16, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher Lucas Prince | Director | President |
| Christopher Lucas Prince | Executive Officer | Chief Executive Officer |
| Christopher Lucas Prince | Director | Secretary |
| Jeffrey Calkins | Director | Treasurer |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Feb 16, 2026 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Verra Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.